Title Page

Article Type: Research Article

- **Title:** Potential impact of outpatient stewardship interventions on antibiotic exposures of
- bacterial pathogens
- 8 **Authors:** Christine Tedijanto,¹ Yonatan H Grad,^{2,3} Marc Lipsitch^{1,2}

- 10 **Author Affiliations:** ¹ Center for Communicable Disease Dynamics, Department of
- Epidemiology, Harvard T.H. Chan School of Public Health, Boston, Massachusetts, USA;
- 12 ² Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public
- 13 Health, Boston, Massachusetts, USA; ³ Division of Infectious Diseases, Brigham and Women's
- Hospital, Harvard Medical School, Boston, Massachusetts, USA
-
- **Corresponding Author:** Christine Tedijanto, ctedijanto@g.harvard.edu
-
- **Manuscript Word Count:** 3,025
-

Abstract

 The relationship between antibiotic stewardship and population levels of antibiotic resistance remains unclear. In order to better understand shifts in selective pressure due to stewardship, we use publicly available data to estimate the effect of changes in prescribing on exposures to frequently used antibiotics experienced by potentially pathogenic bacteria that are asymptomatically colonizing the microbiome. We quantify this impact under four hypothetical stewardship strategies. In one scenario, we estimate that elimination of all unnecessary outpatient antibiotic use could avert 6 to 48% (IQR: 17 to 31%) of exposures across pairwise combinations of sixteen common antibiotics and nine bacterial pathogens. All scenarios demonstrate that stewardship interventions, facilitated by changes in clinician behavior and improved diagnostics, have the opportunity to broadly reduce antibiotic exposures across a range of potential pathogens. Concurrent approaches, such as vaccines aiming to reduce infection incidence, are needed to further decrease exposures occurring in "necessary" contexts.

Introduction

 Antibiotic consumption is a known driver of antibiotic resistance. In developed nations, over 80% of antibiotic consumption for human health occurs in the outpatient setting (European Centre for Disease Prevention and Control, 2018; Public Health Agency of Canada, 2018; Public Health England, 2017; Swedres-Svarm, 2017), and US-based studies conducted across different subpopulations have estimated that 23-40% of outpatient prescriptions may be inappropriate (Chua, Fischer, & Linder, 2019; Fleming-Dutra et al., 2016; Olesen, Barnett, MacFadden, Lipsitch, & Grad, 2018). Inappropriate antibiotic use leads to increased risk of adverse events (Linder, 2008; Shehab, Patel, Srinivasan, & Budnitz, 2008), disruption of colonization resistance and other benefits of the microbial flora (Buffie & Pamer, 2013; Khosravi & Mazmanian, 2013), and bystander selection for antibiotic resistance, with little to no health gains for the patient. Recent work on bystander selection estimates that, for 8 of 9 potential pathogens of interest, over 80% of their exposures to commonly used antibiotic classes in the outpatient setting occur when the organisms are asymptomatically colonizing the microbiome, not causing disease (Tedijanto, Olesen, Grad, & Lipsitch, 2018). A corollary of extensive bystander selection is that reductions in use will prevent antibiotic exposures for species throughout the microbiome.

 We use publicly available data to quantify potentially avertable exposures of bacterial species to commonly used antibiotics under hypothetical changes in prescribing practice. The set of scenarios included here are intended as thought experiments to explore the upper bounds of avertable antibiotic exposures. Reductions in antibiotic consumption have historically had variable impacts on resistance levels, likely dependent on setting, baseline consumption and resistance patterns, and fitness costs (Andersson & Hughes, 2010; Lipsitch, 2001). In addition,

 number of avertable exposures by antibiotic and species, *Tas* be the total number of exposures by antibiotic and species, *daig* be the number of prescriptions of antibiotic *a* associated with diagnosis code *i* in age group *g*, *psig* be the carriage prevalence of species *s* among those with diagnosis code *i* in age group *g*, and *qaig* be the proportion of avertable exposures by diagnosis code and age group in the given scenario. For example, in the scenario assessing elimination of all unnecessary antibiotic use, *qaig* is the proportion of avertable antibiotic use by diagnosis and age group (Fleming-Dutra et al., 2016). Alternatively, in the scenario assessing elimination of non-nitrofurantoin treatment for cystitis, *qaig* is 1 when *a* is not nitrofurantoin and *i* is a diagnosis code associated with cystitis, and 0 elsewhere. Carriage prevalences (*psig*) are assumed to be constant within three age groups (under 1 year, 1-5 years, over 5 years old) (Tedijanto et al., 2018), while proportions of avertable antibiotic use (*qaig*) were reported for three different age groups (0-19 years, 20-64 years, 65 years old and over) (Fleming-Dutra et al., 2016). *G* is the smallest set of age groups that accounts for this granularity (under 1 year, 1-5 years, 6-19 years, 20-64 years, 65 years old and over).

Equation 1. Proportion of avertable exposures by species and antibiotic.

$$
\frac{X_{as}}{T_{as}} = \frac{\sum_{g=1}^{G} \sum_{i=0}^{I} d_{aig} \times p_{sig} \times q_{aig}}{\sum_{g=1}^{G} \sum_{i=0}^{I} d_{aig} \times p_{sig}}
$$

 In scenarios where unnecessary use is eliminated (1 and 2), we assume that only bystander exposures are affected. Equivalently, this presumes that perfect discrimination between bacterial and non-bacterial etiologies is possible. This results in a slight modification to Equation 1 -- *psig* is changed to *ps0g* as all eliminated exposures would have occurred during asymptomatic carriage. For cases where *esig* is 1, we assume zero avertable exposures. In addition, we make slight modifications to *qaig* when we estimate the proportion of bacterial cases to be larger than the proportion of necessary prescriptions (Appendix Table 2). As a sensitivity analysis, we

include the proportion of avertable exposures for each species-antibiotic pair under Scenario 1 if

antibiotic use was eliminated equally across both target and bystander exposures (Appendix

Figure 1). All analysis was conducted in R version 3.5.1.

Results

Results for all four scenarios are depicted in Figure 1. We estimate that elimination of

unnecessary antibiotic prescriptions across all outpatient conditions would prevent 6 to 48%

(IQR: 17 to 31%) of antibiotic-species exposures (Figure 1A). The smallest reduction is

associated with *S. pyogenes* exposures to cefdinir and the largest with *H. influenzae* and *E. coli*

exposures to azithromycin. If all unnecessary antibiotic use could be prevented, over 30% of

exposures to amoxicillin-clavulanate, penicillin, azithromycin, clarithromycin, levofloxacin, and

doxycycline across most potential pathogens of interest could be averted. As expected, the

proportion of avertable exposures when all unnecessary outpatient use is eliminated is positively

correlated with previously reported estimates of bystander selection (Appendix Figure 2)

(Tedijanto et al., 2018).

 Across all scenarios, the proportion of avertable exposures appears to be primarily driven by the drug considered. For example, in both scenarios assessing broad elimination of unnecessary antibiotic use, every species can expect azithromycin exposures to decrease to the greatest extent as it is the most commonly used antibiotic for respiratory conditions for which antibiotics are not indicated (Figure 1B). The estimated reductions in azithromycin across species range from 37 to 48% when all outpatient conditions are considered and from 24 to 32% when limited to the subset of respiratory conditions for which antibiotics are not indicated. High estimates of

 avertable exposures for a particular antibiotic reflect both frequent use for the impacted syndrome(s) and concentrated use for those conditions relative to other indications. Consider the indication-specific scenarios: ciprofloxacin and sulfamethoxazole-trimethoprim are the most frequently prescribed antibiotics for cystitis other than nitrofurantoin and have relatively large estimates of avertable exposures (23 to 44% and 7 to 26%, respectively). While clarithromycin is only the eighth-most-prescribed antibiotic for acute sinusitis among the included antibiotics, its concentrated use for acute sinusitis compared to other indications results in relatively large expected reductions in exposure (up to 9% for *P. aeruginosa* and *S. pyogenes*) compared to other drugs.

Figure 1. Heatmaps showing the estimated percentage of species exposures to each antibiotic or antibiotic class that could be averted if *A:* unnecessary antibiotic prescriptions across all

outpatient conditions, *B:* all antibiotic use for outpatient respiratory conditions for which

antibiotics are not indicated, *C:* all antibiotic use for acute sinusitis, or *D:* non-nitrofurantoin

- treatment of cystitis in women was eliminated. Drug class results include prescriptions of all
- 187 antibiotics in that class, as identified by the Multum Lexicon classification system.
188 Abbreviations: Antibiotics (y-axis): AMX=amoxicillin, AMX-CLAV=amoxicillin-clavulanate, PE
- **Abbreviations:** *Antibiotics (y-axis):* AMX=amoxicillin, AMX-CLAV=amoxicillin-clavulanate, PEN=penicillin, 189 AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides,
- 189 AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides,
190 CIP=ciprofloxacin, LEV=levofloxacin, MXF=moxifloxacin, CFL=cephalexin, CDR=cefdinir, DOX=doxvcvcl
- 190 CIP=ciprofloxacin, LEV=levofloxacin, MXF=moxifloxacin, CFL=cephalexin, CDR=cefdinir, DOX=doxycycline, 191 TET=tetracycline. MNO=minocycline. TMP-SMX=sulfamethoxazole-trimethorim. NIT=nitrofurantoin:
- 191 TET=tetracycline, MNO=minocycline, TMP-SMX=sulfamethoxazole-trimethoprim, NIT=nitrofurantoin;
192 Organisms (x-axis): EC=E. coli, HI=H. influenzae, KP=K. pneumoniae, MC=M. catarrhalis, PA=P. aerug
- *Organisms (x-axis):* EC=*E. coli*, HI=*H. influenzae*, KP=*K. pneumoniae*, MC=*M. catarrhalis*, PA=*P. aeruginosa*,
- SA=*S. aureus*, SAg=*S. agalactiae*, SP=*S. pneumoniae*, SPy=*S. pyogenes*; PY=person-years
-
- Characteristics of the bacterial organism of interest also influence the extent of avertable
- exposures. Species that are common causes of the affected condition(s) naturally have larger
- predicted reductions in exposure. For example, an estimated 33%, 36%, and 44% of
- ciprofloxacin exposures to *E. coli*, *K. pneumoniae*, and *P. aeruginosa*, respectively, could be
- averted under the cystitis scenario, compared to 23 to 27% across all other organisms. Although
- *E. coli* is the most common cause of UTIs, its estimated exposure reduction in this scenario is
- lower than that of *P. aeruginosa*, likely due to the larger number of bystander exposures incurred
- by *E. coli* during asymptomatic carriage. Infrequent carriage prevalence in the normal
- microbiome is also generally associated with lower proportions of avertable exposures across all
- antibiotics (e.g. *S. pyogenes, S. agalactiae*, *M. catarrhalis*).
-

Discussion

 We quantify the species-level impact of changes in antibiotic consumption as the proportion of antibiotic exposures experienced by common bacterial pathogens that could be averted under four hypothetical scenarios. In the scenario where unnecessary antibiotic use for all outpatient conditions is eliminated, we find that up to 48% of exposures (of *H. influenzae* and *E. coli* to azithromycin) could be avoided. In addition, impact of the intervention across antibiotics and species is widespread, with half of antibiotic-species pairs expected to experience a reduction in exposures of over one fifth (22%). For conditions which require antibiotic treatment, such as

 UTIs, switching to antibiotics with decreased collateral damage to the microbiome, such as nitrofurantoin, may be an effective strategy for reducing antibiotic exposures across species.

 In three out of four situations we assess, antibiotics are considered entirely unnecessary for some or all cases. This is a strong assumption in the case of acute sinusitis, as a small number of cases are truly bacterial and antibiotics are indicated for patients with persistent, severe or worsening symptoms (Rosenfeld et al., 2015). These scenarios are explored in sensitivity analyses (Appendix Figure 3). In the future, this method may also be extended to measure net changes in exposures resulting from more nuanced scenarios where one antibiotic is substituted for another. We did not assess such changes for nitrofurantoin, as its effects on the microbiome outside of the bladder are thought to be minimal (Stewardson et al., 2015). The reductions in use presented here may be practically infeasible due to challenges including similar clinical presentation of viral and bacterial infections, individual considerations such as allergies (Sakoulas, Geriak, & Nizet, 2018) or heightened risk of adverse events, misdiagnosis (Filice et al., 2015; Tomas, Getman, Donskey, & Hecker, 2015), and patient-driven demand (Vanden Eng et al., 2003). Even if elimination of unnecessary use were fully realized, our results imply that the majority of species' antibiotic exposures occur in the context of "necessary" antibiotic use. These findings underscore the importance of considering bystander effects and the need for a multi-pronged approach to programs aimed at controlling antibiotic resistance. Rapid diagnostics, diagnostics that accurately discriminate between bacterial and non-bacterial causes, patient education, and improved decision-making tools and other interventions to motivate changes in clinician behavior can enhance responsible antibiotic consumption; these should be implemented simultaneously with prevention measures such as infection control, access to clean water and

 sanitation, safe sex interventions, and vaccination, which aim to reduce infection incidence and thus any antibiotic use.

 At the time of this analysis, Fleming-Dutra et al. remained the most up-to-date source of unnecessary antibiotic prescribing by condition. Recent work with slightly different methods found a lower proportion of inappropriate antibiotic prescriptions overall (23.2% compared to 30%) but did not report their estimates by condition (Chua et al., 2019). Although comparable estimates of unnecessary prescribing over time are unavailable, multiple studies have shown that declines in antibiotic use from approximately 2011 to 2016 in the United States have been primarily due to pediatric prescribing, implying that, at least for adults, levels of unnecessary prescribing likely remained similar (Durkin et al., 2018; King, Bartoces, Fleming-Dutra, Roberts, & Hicks, 2019; Klevens et al., 2019; Olesen et al., 2018). Finally, we assume that the proportion of unnecessary use is constant across antibiotics used for the same condition as it is difficult to identify specific antibiotic prescriptions that were unwarranted without detailed chart review. A study among outpatients in the Veterans Affairs medical system found that among prescriptions for community-acquired pneumonia, sinusitis, and acute exacerbations of chronic bronchitis, the highest proportion of macrolide use was inappropriate (27%), followed by penicillins (22%) and quinolones (12%) (Tobia, Aspinall, Good, Fine, & Hanlon, 2008). Similar studies are needed to understand which antibiotics are frequently used inappropriately for other indications and settings.

 Reductions in antibiotic consumption are necessary to preserve the potency of these drugs. Quantifying changes in species-level exposures due to stewardship programs is one more step towards understanding how changes in antibiotic use correspond to antibiotic resistance at the population level. Further research, integrating knowledge from clinical, ecological, and evolutionary spheres, is needed to elucidate this relationship (MacLean & San Millan, 2019).

- The methods presented here may be easily extended to incorporate other data sources, such as
- claims, or to assess more specific stewardship programs. We show that while improved
- prescribing practices have the potential to prevent antibiotic exposures experienced by bacterial
- species throughout the microbiome, complementary efforts to facilitate appropriate antibiotic
- consumption and decrease overall infection incidence are required to substantially avert
- exposures.

Acknowledgements

- We thank Dr. Lauri Hicks for her helpful comments on this manuscript.
-

Competing Interests

- ML has received consulting income from Affinivax, Antigen Discovery, Merck, and Pfizer and
- research grants through Harvard School of Public Health from Pfizer and PATH. YHG has
- received consulting income from Merck and GlaxoSmithKline. The authors have no other
- relationships or activities that could appear to have influenced the submitted work.
-

Funding Sources

- This work was supported by Grant U54GM088558 (Models of Infectious Disease Agent Study,
- Center for Communicable Disease Dynamics) from the National Institute of General Medical
- Sciences, Grant R01AI132606 from the National Institute of Allergy and Infectious Diseases (to
- YHG), Grant CK000538-01 from the Centers for Disease Control and Prevention, and the Doris
- Duke Charitable Foundation. CT is supported by Grant T32AI007535 from the National Institute
- of Allergy and Infectious Diseases. The content is solely the responsibility of the authors and
- does not necessarily represent the official views of the National Institute of General Medical
- Sciences, National Institutes of Health, National Institute of Allergy and Infectious Diseases,
- Centers for Disease Control and Prevention, Department of Health and Human Services, or the
- Doris Duke Charitable Foundation.
-
-

References

-
- Aitken, M., & Taylor, J. A. (1998). Prevalence of Clinical Sinusitis in Young Children Followed
- Up by Primary Care Pediatricians. *Archives of Pediatrics & Adolescent Medicine*, *152*(3),
- 244–248. https://doi.org/10.1001/archpedi.152.3.244
- Andersson, D. I., & Hughes, D. (2010). Antibiotic resistance and its cost: Is it possible to reverse
- resistance? *Nature Reviews Microbiology*, *8*(4), 260–271.
- https://doi.org/10.1038/nrmicro2319
- Benninger, M. S., Holzer, S. E. S., & Lau, J. (2000). Diagnosis and treatment of uncomplicated
- acute bacterial rhinosinusitis: Summary of the Agency for Health Care Policy and
- Research evidence-based report. *Otolaryngology–Head and Neck Surgery*, *122*(1), 1–7.
- https://doi.org/10.1016/S0194-5998(00)70135-5
- Bluestone, C. D., Stephenson, J. S., & Martin, L. M. (1992). Ten-year review of otitis media

pathogens. *The Pediatric Infectious Disease Journal*, *11*(8), S7–S11.

https://doi.org/10.1097/00006454-199208001-00002

- Brook, I. (2016). Microbiology of chronic rhinosinusitis. *European Journal of Clinical*
- *Microbiology & Infectious Diseases*, *35*(7), 1059–1068. https://doi.org/10.1007/s10096-
- 016-2640-x
- Bruyndonckx, R., Hens, N., Aerts, M., Goossens, H., Molenberghs, G., & Coenen, S. (2014).
- Measuring trends of outpatient antibiotic use in Europe: Jointly modelling longitudinal
- data in defined daily doses and packages. *Journal of Antimicrobial Chemotherapy*, *69*(7),
- 1981–1986. https://doi.org/10.1093/jac/dku063

- Buffie, C. G., & Pamer, E. G. (2013). Microbiota-mediated colonization resistance against
- intestinal pathogens. *Nature Reviews Immunology*, *13*(11), 790–801.
- https://doi.org/10.1038/nri3535
- Burgstaller, J. M., Steurer, J., Holzmann, D., Geiges, G., & Soyka, M. B. (2016). Antibiotic
- efficacy in patients with a moderate probability of acute rhinosinusitis: A systematic
- review. *European Archives of Oto-Rhino-Laryngology*, *273*(5), 1067–1077.
- https://doi.org/10.1007/s00405-015-3506-z
- Celin, S. E. (1991). Bacteriology of Acute Otitis Media in Adults. *JAMA*, *266*(16), 2249–2252.
- https://doi.org/10.1001/jama.266.16.2249
- Chua, K.-P., Fischer, M. A., & Linder, J. A. (2019). Appropriateness of outpatient antibiotic
- prescribing among privately insured US patients: ICD-10-CM based cross sectional study. *BMJ*, *364*(k5092). https://doi.org/10.1136/bmj.k5092
- Durkin, M. J., Jafarzadeh, S. R., Hsueh, K., Sallah, Y. H., Munshi, K. D., Henderson, R. R., &
- Fraser, V. J. (2018). Outpatient Antibiotic Prescription Trends in the United States: A
- National Cohort Study. *Infection Control & Hospital Epidemiology*, *39*(5), 584–589.
- https://doi.org/10.1017/ice.2018.26
- European Centre for Disease Prevention and Control. (2018). *Antimicrobial consumption: Annual epidemiological report for 2017*. Stockholm.
- Filice, G. A., Drekonja, D. M., Thurn, J. R., Hamann, G. M., Masoud, B. T., & Johnson, J. R.
- (2015). Diagnostic Errors that Lead to Inappropriate Antimicrobial Use. *Infection Control & Hospital Epidemiology*, *36*(8), 949–956. https://doi.org/10.1017/ice.2015.113
- Fleming-Dutra, K. E., Hersh, A. L., Shapiro, D. J., Bartoces, M., Enns, E. A., File, T. M., …
- Hicks, L. A. (2016). Prevalence of Inappropriate Antibiotic Prescriptions Among US

- Ambulatory Care Visits, 2010-2011. *JAMA*, *315*(17), 1864–1873.
- https://doi.org/10.1001/jama.2016.4151
- Gupta, K., Hooton, T. M., Naber, K. G., Wullt, B., Colgan, R., Miller, L. G., … Soper, D. E.
- (2011). International Clinical Practice Guidelines for the Treatment of Acute
- Uncomplicated Cystitis and Pyelonephritis in Women: A 2010 Update by the Infectious
- Diseases Society of America and the European Society for Microbiology and Infectious
- Diseases. *Clinical Infectious Diseases*, *52*(5), e103–e120.
- https://doi.org/10.1093/cid/ciq257
- Gupta, K., Scholes, D., & Stamm, W. E. (1999). Increasing prevalence of antimicrobial
- resistance among uropathogens causing acute uncomplicated cystitis in women. *JAMA*,

281(8), 736–738. https://doi.org/10.1001/jama.281.8.736

- Huttenhower, C., Gevers, D., Knight, R., Abubucker, S., Badger, J. H., Chinwalla, A. T., …
- White, O. (2012). Structure, function and diversity of the healthy human microbiome.

Nature, *486*(7402), 207–214. https://doi.org/10.1038/nature11234

- Kabbani, S., Hersh, A. L., Shapiro, D. J., Fleming-Dutra, K. E., Pavia, A. T., & Hicks, L. A.
- (2018). Opportunities to Improve Fluoroquinolone Prescribing in the United States for
- Adult Ambulatory Care Visits. *Clinical Infectious Diseases*, *67*(1), 134–136.
- https://doi.org/10.1093/cid/ciy035
- Khosravi, A., & Mazmanian, S. K. (2013). Disruption of the gut microbiome as a risk factor for
- microbial infections. *Current Opinion in Microbiology*, *16*(2), 221–227.
- https://doi.org/10.1016/j.mib.2013.03.009

- King, L. M., Bartoces, M., Fleming-Dutra, K. E., Roberts, R. M., & Hicks, L. A. (2019).
- Changes in US Outpatient Antibiotic Prescriptions from 2011-2016. *Clinical Infectious*
- *Diseases*. https://doi.org/10.1093/cid/ciz225
- Klevens, R. M., Caten, E., Olesen, S. W., DeMaria, A., Troppy, S., & Grad, Y. H. (2019).
- Outpatient antibiotic prescribing in Massachusetts, 2011-2015. *Open Forum Infectious*
- *Diseases*, *6*(5), ofz169. https://doi.org/10.1093/ofid/ofz169
- Linder, J. A. (2008). *Editorial Commentary:* Antibiotics for Treatment of Acute Respiratory
- Tract Infections: Decreasing Benefit, Increasing Risk, and the Irrelevance of
- Antimicrobial Resistance. *Clinical Infectious Diseases*, *47*(6), 744–746.
- https://doi.org/10.1086/591149
- Lipsitch, M. (2001). The rise and fall of antimicrobial resistance. *Trends in Microbiology*, *9*(9),
- 438–444. https://doi.org/10.1016/S0966-842X(01)02130-8
- MacLean, R. C., & San Millan, A. (2019). The evolution of antibiotic resistance. *Science*,

365(6458), 1082–1083. https://doi.org/10.1126/science.aax3879

- Olesen, S. W., Barnett, M. L., MacFadden, D. R., Lipsitch, M., & Grad, Y. H. (2018). Trends in
- outpatient antibiotic prescribing practice among US older adults, 2011-2015: An
- observational study. *BMJ*, *362*, k3155. https://doi.org/10.1136/bmj.k3155
- Public Health Agency of Canada. (2018). *Canadian Antimicrobial Resistance Surveillance System 2017 Report*.
- Public Health England. (2017). *English Surveillance Programme for Antimicrobial Utilisation and Resistance (ESPAUR) 2017*.
- Rosenfeld, R. M., Piccirillo, J. F., Chandrasekhar, S. S., Brook, I., Ashok Kumar, K., Kramper,
- M., … Corrigan, M. D. (2015). Clinical Practice Guideline (Update): Adult Sinusitis.

Otolaryngology–Head and Neck Surgery, *152*(2_suppl), S1–S39.

- https://doi.org/10.1177/0194599815572097
- Sakoulas, G., Geriak, M., & Nizet, V. (2018). Is a Reported Penicillin Allergy Sufficient
- Grounds to Forgo the Multidimensional Antimicrobial Benefits of β-Lactam Antibiotics?

Clinical Infectious Diseases, *68*, 157–164. https://doi.org/10.1093/cid/ciy557

- Sande, M. A., & Gwaltney, J. M. (2004). Acute Community-Acquired Bacterial Sinusitis:
- Continuing Challenges and Current Management. *Clinical Infectious Diseases*,
- *39*(Supplement_3), S151–S158. https://doi.org/10.1086/421353
- Shehab, N., Patel, P. R., Srinivasan, A., & Budnitz, D. S. (2008). Emergency Department Visits
- for Antibiotic‐Associated Adverse Events. *Clinical Infectious Diseases*, *47*(6), 735–743. https://doi.org/10.1086/591126
- Smith, S. S., Evans, C. T., Tan, B. K., Chandra, R. K., Smith, S. B., & Kern, R. C. (2013).
- National burden of antibiotic use for adult rhinosinusitis. *Journal of Allergy and Clinical*

Immunology, *132*(5), 1230–1232. https://doi.org/10.1016/j.jaci.2013.07.009

- Snow, V., Mottur-Pilson, C., Hickner, J. M., & for the American College of Physicians–
- American Society of Internal Medicine*. (2001). Principles of Appropriate Antibiotic
- Use for Acute Sinusitis in Adults. *Annals of Internal Medicine*, *134*(6), 495.

https://doi.org/10.7326/0003-4819-134-6-200103200-00016

- Stewardson, A. J., Gaïa, N., François, P., Malhotra-Kumar, S., Delémont, C., Martinez de
- Tejada, B., … Lazarevic, V. (2015). Collateral damage from oral ciprofloxacin versus
- nitrofurantoin in outpatients with urinary tract infections: A culture-free analysis of gut
- microbiota. *Clinical Microbiology and Infection*, *21*(4), 344.e1-344.e11.
- https://doi.org/10.1016/j.cmi.2014.11.016

- *Sweden*. Public Health Agency of Sweden and National Veterinary Institute.
- Tedijanto, C., Olesen, S. W., Grad, Y. H., & Lipsitch, M. (2018). Estimating the proportion of
- bystander selection for antibiotic resistance among potentially pathogenic bacterial flora.
- *Proceedings of the National Academy of Sciences*, *115*(51), E11988–E11995.
- https://doi.org/10.1073/pnas.1810840115
- The Human Microbiome Project Consortium. (2012). A framework for human microbiome research. *Nature*, *486*(7402), 215–221. https://doi.org/10.1038/nature11209
- Tobia, C., Aspinall, S., Good, C., Fine, M., & Hanlon, J. (2008). Appropriateness of antibiotic
- prescribing in veterans with community-acquired pneumonia, sinusitis, or acute
- exacerbations of chronic bronchitis: A cross-sectional study. *Clinical Therapeutics*,

30(6), 1135–1144. https://doi.org/10.1016/j.clinthera.2008.06.009

- Tomas, M. E., Getman, D., Donskey, C. J., & Hecker, M. T. (2015). Overdiagnosis of Urinary
- Tract Infection and Underdiagnosis of Sexually Transmitted Infection in Adult Women
- Presenting to an Emergency Department. *Journal of Clinical Microbiology*, *53*(8), 2686–
- 2692. https://doi.org/10.1128/JCM.00670-15
- Vanden Eng, J., Marcus, R., Hadler, J. L., Imhoff, B., Vugia, D. J., Cieslak, P. R., … Besser, R.
- E. (2003). Consumer Attitudes and Use of Antibiotics. *Emerging Infectious Diseases*,
- *9*(9), 1128–1135. https://doi.org/10.3201/eid0909.020591
- Wald, E. R., Guerra, N., & Byers, C. (1991). Upper Respiratory Tract Infections in Young
- Children: Duration of and Frequency of Complications. *Pediatrics*, *87*(2), 129–133.

- Williams, J. W., Simel, D. L., Roberts, L., & Samsa, G. P. (1992). Clinical Evaluation for
- Sinusitis. *Annals of Internal Medicine*, *117*(9), 705–710. https://doi.org/10.7326/0003-
- 4819-117-9-705

479 **Appendix Table 2.** Modifications to proportions of unnecessary antibiotic prescriptions based

480 on published etiology studies and antibiotic use in NAMCS/NHAMCS. Modifications were

481 made if the reported proportion of bacterial cases for a given condition exceeded the estimated

482 proportion of appropriate prescriptions reported in Fleming-Dutra et al. (Fleming-Dutra et al.,

483 2016)

Appendix Figure 1. Sensitivity analysis of proportions of avertable exposures across all

 outpatient conditions when proportion of unnecessary use is applied equally across target and bystander exposures (Equation 1 without modification).

492 **Abbreviations:** *Antibiotics (y-axis):* AMX=amoxicillin, AMX-CLAV=amoxicillin-clavulanate, PEN=penicillin,
493 AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides,

AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides,

494 CIP=ciprofloxacin, LEV=levofloxacin, MXF=moxifloxacin, CFL=cephalexin, CDR=cefdinir, DOX=doxycycline, 495 TET=tetracycline, MNO=minocycline, TMP-SMX=sulfamethoxazole-trimethorim, NIT=nitrofurantoin;

495 TET=tetracycline, MNO=minocycline, TMP-SMX=sulfamethoxazole-trimethoprim, NIT=nitrofurantoin;
496 *Organisms (x-axis):* EC=E, coli, HI=H, influenzae, KP=K, pneumoniae, MC=M, catarrhalis, PA=P, aerus

Organisms (x-axis): EC=*E. coli*, HI=*H. influenzae*, KP=*K. pneumoniae*, MC=*M. catarrhalis*, PA=*P. aeruginosa*,

SA=*S. aureus*, SAg=*S. agalactiae*, SP=*S. pneumoniae*, SPy=*S. pyogenes*; PY=person-years

Appendix Figure 2. Proportion of avertable exposures when all unnecessary use for outpatient conditions is eliminated against proportion of bystander exposures (Tedijanto et al., 2018). conditions is eliminated against proportion of bystander exposures (Tedijanto et al., 2018).

- **Appendix Figure 3.** Sensitivity analysis for Scenario 3 (elimination of all antibiotic use for
- acute sinusitis).

A. Use estimates of bacterial etiology to approximate appropriate antibiotic use for acute

- **sinusitis.** The following upper bound estimates for the proportion of acute sinusitis cases with
- bacterial etiology were used: 2% for adults and 13% for children (applied to 0-19 year old age
- group) (Sande & Gwaltney, 2004; Snow, Mottur-Pilson, Hickner, & for the American College of
- Physicians–American Society of Internal Medicine*, 2001; Wald, Guerra, & Byers, 1991)**.**

B. Use estimates of bacterial etiology among those presenting to primary care clinics.

- Patients visiting the clinic are likely to have more persistent, severe, or worsening symptoms,
- which may be indications of bacterial etiology. Studies have estimated that approximately 38%
- of adults and 17% of children (upper bounds) visiting primary care for symptoms of acute upper
- respiratory tract infection have bacterial rhinosinusitis (Aitken & Taylor, 1998; Benninger,
- Holzer, & Lau, 2000; Williams, Simel, Roberts, & Samsa, 1992).

-
- 521 **Abbreviations:** *Antibiotics (y-axis)*: AMX=amoxicillin, AMX-CLAV=amoxicillin-clavulanate, PEN=penicillin,
522 AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides,
523 CIP= AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides,
- 523 CIP=ciprofloxacin, LEV=levofloxacin, MXF=moxifloxacin, CFL=cephalexin, CDR=cefdinir, DOX=doxycycline,
- 524 TET=tetracycline, MNO=minocycline, TMP-SMX=sulfamethoxazole-trimethoprim, NIT=nitrofurantoin; *Organisms (x-axis):*
- 525 EC=*E. coli*, HI=*H. influenzae*, KP=*K. pneumoniae*, MC=*M. catarrhalis*, PA=*P. aeruginosa*, SA=*S. aureus*, SAg=*S. agalactiae*,
- 526 SP=*S. pneumoniae*, SPy=*S. pyogenes*; PY=person-years

- **Appendix Figure 4.** Proportions of avertable exposures using 2010-2011 NAMCS/NHAMCS
- data with *(left)* and without *(right)* NHAMCS outpatient department data.

A. Eliminate unnecessary antibiotic use across all outpatient conditions.

B. Eliminate all antibiotic use for outpatient respiratory conditions for which antibiotics

are not indicated.

C. Eliminate all antibiotic use for acute sinusitis.

D. Prescribe nitrofurantoin for all cases of cystitis in women.

AZM=azithromycin, CLI=clindamycin, CLR=clarithromycin, MACR/LINC=all macrolides and lincosamides,

- CIP=ciprofloxacin, LEV=levofloxacin, MXF=moxifloxacin, CFL=cephalexin, CDR=cefdinir, DOX=doxycycline,
- TET=tetracycline, MNO=minocycline, TMP-SMX=sulfamethoxazole-trimethoprim, NIT=nitrofurantoin; *Organisms (x-axis):*

EC=*E. coli*, HI=*H. influenzae*, KP=*K. pneumoniae*, MC=*M. catarrhalis*, PA=*P. aeruginosa*, SA=*S. aureus*, SAg=*S. agalactiae*,

SP=*S. pneumoniae*, SPy=*S. pyogenes*; PY=person-years